Biomechanical 3D tumor models on a micro-milled high-throughput force sensor array https://www.biorxiv.org/content/10.1101/2025.09.22.677940v1

Breast Cancer Subtyping with HyperCLSA: A Hypergraph Contrastive Learning Pipeline for Multi-Omics Data Integration https://www.biorxiv.org/content/10.1101/2025.09.22.677517v1

Role of tankyrase scaffolding in the β-catenin destruction complex and WNT signaling https://www.biorxiv.org/content/10.1101/2025.09.22.677768v1

Signatures of Micropeptides Encoded by lncRNAs in Cancer Progression and Metastasis https://www.biorxiv.org/content/10.1101/2025.09.22.677872v1

ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target https://www.biorxiv.org/content/10.1101/2025.09.23.678089v1

Dual Modes of Gene Regulation by CDK12 https://www.biorxiv.org/content/10.1101/2025.09.22.677923v1

RB1 gene mutations and their association with Endometrial Cancer https://www.biorxiv.org/content/10.1101/2025.09.22.677485v1

SRF fusion oncogenes encode constitutively activated chimeric transcription factors in myoid soft tissue tumors https://www.biorxiv.org/content/10.1101/2025.09.18.676997v1

Selective degradation of oncogenic extrachromosomal DNA by type I-E CRISPR https://www.biorxiv.org/content/10.1101/2025.09.21.677573v1

Spatially organized lymphocytic microenvironments in high grade primary prostate tumors https://www.biorxiv.org/content/10.1101/2025.09.21.677465v1

Tumor Organoids Modeling Reveals Timed Responses and Interplay of Radiotherapy and Chemotherapy in Pancreatic Cancer https://www.biorxiv.org/content/10.1101/2025.09.21.677544v1

FOXO1 inhibition and FADD knockdown have opposing effects on anticancer drug-induced cytotoxicity and p21 expression in osteosarcoma https://www.biorxiv.org/content/10.1101/2025.09.20.677161v1

Lymph-node transcriptomics define prognostic immune states in mucosal melanoma and reveal IBA1 as a practical biomarker for improved prognosis https://www.biorxiv.org/content/10.1101/2025.09.20.677500v1

Bile Salts and Bacterial Bile Salt Hydrolase Activity Differentially Influence Escherichia coli Colonization and FXR Signaling in Colorectal Cancer Organoids https://www.biorxiv.org/content/10.1101/2025.09.20.676381v1

Candida albicans infiltrates colon and rectal cancers causing therapeutic resistance and decreased survival https://www.biorxiv.org/content/10.1101/2025.09.19.677366v1

Tumor intrinsic regulation of PD-L1 and of interferon Type I via an SLC25A1-driven mitochondrial pathway, influences the anti-tumor immune response https://www.biorxiv.org/content/10.1101/2025.09.20.677512v1

The tissue specificity of cancer genes https://www.biorxiv.org/content/10.1101/2025.09.21.677175v1

Dietary α-Ketoglutarate delays lung adenocarcinoma in females and modulates TBX5-associated transcriptional programs and the immune microenvironment https://www.biorxiv.org/content/10.1101/2025.09.19.677388v1

Leveraging Experimental Evolution to Extract Predictive Collateral Drug Response Signatures in Ewings Sarcoma https://www.biorxiv.org/content/10.1101/2025.09.19.677399v1

Dietary Patterns and Gene Expression Profiles in Gastric Adenocarcinoma Patients from the Northern Region of Brazil https://www.biorxiv.org/content/10.1101/2025.09.17.676793v1

Epithelial-Mesenchymal Plasticity is Associated with Immunosuppressive Features in Canine Mammary Carcinomas https://www.biorxiv.org/content/10.1101/2025.09.19.677414v1

A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer https://www.biorxiv.org/content/10.1101/2025.09.18.677116v1

RRAS and RRAS2 mutations are oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236 https://www.biorxiv.org/content/10.1101/2025.09.19.677259v1

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy https://www.biorxiv.org/content/10.1101/2025.09.18.677171v1

Myofibroblastic CAFs arising from bone-resident osteoblast precursors retain an osteolineage signature and support breast cancer progression via Osterix-mediated signaling. https://www.biorxiv.org/content/10.1101/2025.09.18.677154v1

E2f coordinates the proliferation and transdifferentiation of a Sox9+bile duct cell to initiate hepatocellular carcinoma https://www.biorxiv.org/content/10.1101/2025.09.18.677170v1

GLIS3 Marks a Neural-like Progenitor Cell State that Drives Metastasis in Pancreatic Ductal Adenocarcinoma https://www.biorxiv.org/content/10.1101/2025.09.18.677140v1

Discovery of circulating cell-free DNA 5hmC biomarkers for peritoneal metastasis in colorectal and appendiceal cancer https://www.biorxiv.org/content/10.1101/2025.09.18.676945v1

PDAC tumor immune system escape architecture: Analysis of transcriptomics of mechanisms that TME is tackling immune system in Pancreatic Ductal Adenocarcinoma Tumors https://www.biorxiv.org/content/10.1101/2025.09.18.677181v1

Aberrant inheritance of extrachromosomal DNA amplifications promotes cancer evolution https://www.biorxiv.org/content/10.1101/2025.09.19.677276v1

Type I interferon signaling instills divergent metastatic phenotypes and immunotherapy responses https://www.biorxiv.org/content/10.1101/2025.09.18.677123v1

Bridging biology and statistics with hybrid Bayesian experimental design for drug dose-response assays https://www.biorxiv.org/content/10.1101/2025.09.18.677072v1

Therapeutic poxviruses induce the secretion of immunostimulating and anti-tumoral extracellular vesicles https://www.biorxiv.org/content/10.1101/2025.09.19.677320v1

Moonlighting Role of Meiotic SYCP1 in Breast Cancer: A Chromatin-Bound Regulator of DNA Repair, Transcription, and Drug Resistance https://www.biorxiv.org/content/10.1101/2025.09.18.677087v1

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer https://www.biorxiv.org/content/10.1101/2025.09.19.675739v1

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma https://www.biorxiv.org/content/10.1101/2025.09.18.675797v1

Quercetin as a Bitter Taste Receptor Agonist with Anticancer Effects in Head and Neck Cancer Cells https://www.biorxiv.org/content/10.1101/2025.09.17.676947v1

Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance https://www.biorxiv.org/content/10.1101/2025.09.17.676669v1

Beckwith-Wiedemann syndrome multiomic analysis of hepatoblastoma uncovers unique tumor heterogeneity and cellular landscapes, including transition cells leading to tumor formation https://www.biorxiv.org/content/10.1101/2025.09.17.676802v1

Understanding proneural-mesenchymal transition using patient-derived glioma stem-like cell (GSC) organoids and engineered extracellular matrix https://www.biorxiv.org/content/10.1101/2025.09.17.676829v1

Cancer-Testis Antigens as Clinical and Prognostic Biomarkers in Gastric Adenocarcinoma: Integration of Differential Expression, Clinical Associations, Survival, and Co-Expression Networks https://www.biorxiv.org/content/10.1101/2025.09.17.676427v1

FLASH or flare: variable intestinal toxicity results in a mouse model following proton pencil beam scanning irradiation on a clinical superconducting synchrocyclotron https://www.biorxiv.org/content/10.1101/2025.09.17.676536v1

siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor Cells https://www.biorxiv.org/content/10.1101/2025.09.17.676969v1

RESTRICT-seq enables time-gated CRISPR screens and uncovers novel epigenetic dependencies of SCC resistance https://www.biorxiv.org/content/10.1101/2025.09.17.676440v1

Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapy https://www.biorxiv.org/content/10.1101/2025.09.17.676884v1

Repurposing passenger amplifications as Trojan horses identifies MPZL1 as a potent target for solid cancers https://www.biorxiv.org/content/10.1101/2025.09.17.675062v1

ADAMTS3 as a promising novel biomarker for the diagnosis of hepatocellular carcinoma https://www.biorxiv.org/content/10.1101/2025.09.17.676767v1

An Investigation of mini-GRID Radiation therapy with Immune Checkpoint Blockade in a Murine Tumor Model https://www.biorxiv.org/content/10.1101/2025.09.14.676104v1

Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance https://www.biorxiv.org/content/10.1101/2025.09.16.676608v1

ARID1A and ARID1B safeguard B cell identity, prevent myeloid transformation and expose therapeutic vulnerabilities in lymphoma https://www.biorxiv.org/content/10.1101/2025.09.16.676393v1